Logo - International Journal of Pharmaceutical Compounding

Stability and In Vitro Toxicity of an Infliximab Eye Drop Formulation

Author(s):  Robert Marie-Claude, Spurr-Michaud Sandra, Frenette Mathieu, Young David, Gipson Ilene K, Dohlman Claes H

Issue:  Sep/Oct 2014 - Volume 18, Number 5
View All Articles in Issue

Abstract:  The purpose of this study was to develop a novel 10-mg/mL infliximab eye drop, to characterize its physical and biological stability under recommended storage conditions, and to assess the formulation’s toxicity to ocular surface epithelium in vitro. Infliximab (10 mg/mL) was reconstituted using equal volumes of sterile water and 1% carboxymethylcellulose artificial tears. Aliquots were stored in either a 4oC refrigerator or -20oC freezer for up to 45 days. Physical stability was assessed through monitoring the solution’s appearance, pH, ultraviolet-visiblenear infrared absorbance and scattering, as well as protein gel electrophoresis. Biological stability was assayed through binding to tumor necrosis factor-alpha using an enzyme-linked immunosorbent assay. In vitro cytotoxicity to human corneal-limbal epithelial cells was examined following a 4-hour exposure to the study drug. Refrigerated and frozen infliximab eye drops remained clear and colorless for the duration of study. The formulation’s pH (7.0) was comparable to that of the artificial tear vehicle alone. Low levels of ultraviolet-visible-near infrared light absorbance and scattering established the lack of protein precipitate after refrigeration or freezing. Protein gel electrophoresis performed under reducing conditions revealed the presence of two main protein bands of approximately 50 kDa and 25 kDa, representing immunoglobulin G heavy and light chains. The migration pattern of the proteins did not change under the different storage conditions and between day 10 and 45 after formulation. Infliximab binding to tumor necrosis factor-alpha remained stable for up to 45 days, with conservation of 101% and 102% of its initial binding activity when refrigerated or frozen, respectively. In vitro human corneal-limbal epithelial cultures showed no increase in cytotoxicity with infliximab treatment when compared to vehicle and culture media controls (P > 0.05). Infliximab can be formulated as an eye drop and remains stable when stored in accordance with current regulations regarding compounded eye drops. The demonstrated physical and biological stability as well as in vitro innocuity of this infliximab eye drop formulation may facilitate future clinical investigation targeting tumor necrosis factor-alpha as a modulator of various ocular surface diseases.

Related Keywords: Marie-Claude Robert, MD, Sandra Spurr-Michaud, MS, Mathieu Frenette, PhD, David Young, RPh, Ilene K. Gipson, PhD, Claes H. Dohlman, MD, PhD, ocular surface diseases, eye disorders, tumor necrosis factor alpha, monoclonal immunoglobulin G antibody, uveitis, dry eye, topical preparations, eye drops, ocular administration

Related Categories: OPHTHALMICS, STABILITIES, COMPATIBILITIES, ADVERSE DRUG EVENTS, ALLERGY/IMMUNOLOGY/INFLAMMATION

Purchase this article for download in electronic PDF format from IJPC at for $35 at:
http://www.ijpc.com/Products/ProductAddToCart.cfm?PID=3891

Search the entire IJPC archive by keyword, topic, or issue at:
http://ijpc.com/Products